BG105069A - Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same - Google Patents

Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same

Info

Publication number
BG105069A
BG105069A BG105069A BG10506900A BG105069A BG 105069 A BG105069 A BG 105069A BG 105069 A BG105069 A BG 105069A BG 10506900 A BG10506900 A BG 10506900A BG 105069 A BG105069 A BG 105069A
Authority
BG
Bulgaria
Prior art keywords
irbesartan
habit
obtaining
methods
pharmaceutical compositions
Prior art date
Application number
BG105069A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bruno Franc
Christian Hoff
San Kiang
Mark Lindrud
Oliver MONNIER
Chenkou Wei
Original Assignee
Sanofi - Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9527829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG105069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi - Synthelabo filed Critical Sanofi - Synthelabo
Publication of BG105069A publication Critical patent/BG105069A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
BG105069A 1998-06-24 2000-12-19 Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same BG105069A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808037A FR2780403B3 (fr) 1998-06-24 1998-06-24 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
PCT/FR1999/001372 WO1999067236A1 (fr) 1998-06-24 1999-06-10 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
BG105069A true BG105069A (en) 2001-11-30

Family

ID=9527829

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105069A BG105069A (en) 1998-06-24 2000-12-19 Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same

Country Status (25)

Country Link
US (2) US6800761B1 (ru)
EP (1) EP1089994B9 (ru)
JP (1) JP2002518495A (ru)
KR (1) KR20010034917A (ru)
CN (1) CN1127499C (ru)
AT (1) ATE275562T1 (ru)
AU (1) AU747887B2 (ru)
BG (1) BG105069A (ru)
BR (1) BR9912198A (ru)
CA (1) CA2335545A1 (ru)
CZ (1) CZ292868B6 (ru)
DE (1) DE69920017T2 (ru)
EA (1) EA003410B1 (ru)
FR (1) FR2780403B3 (ru)
HU (1) HUP0103913A3 (ru)
ID (1) ID27377A (ru)
IL (1) IL140419A0 (ru)
NO (1) NO317786B1 (ru)
NZ (1) NZ508842A (ru)
PL (1) PL345215A1 (ru)
SK (1) SK20032000A3 (ru)
TR (1) TR200003842T2 (ru)
UA (1) UA55540C2 (ru)
WO (1) WO1999067236A1 (ru)
ZA (1) ZA200007588B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453826A1 (en) * 2001-12-10 2004-09-08 Dr. Reddy's Laboratories Ltd. Amorphous form of 2-n-butyl-3-[[2-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4'] non-1-en-4-one
CN101165062A (zh) 2003-01-16 2008-04-23 特瓦制药工业有限公司 伊贝沙坦的新合成方法
AU2007202693B2 (en) * 2003-01-20 2009-12-10 Novartis Ag Process for modifying drug crystal formation
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
ES2310281T3 (es) * 2003-02-05 2009-01-01 Teva Pharmaceutical Industries Limited Sintesis de 2-butil-3-(2'-(1-tritil-1h-tetrazol-5-il)bifenil-4-il)-1,3-diazaspiro-4,4-nonen-4-ona.
RU2006109543A (ru) * 2003-08-27 2007-10-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Производные циклоалкиламинокислот, способы их получения и применение
EP1751123A4 (en) * 2004-05-20 2010-06-30 Reddys Lab Ltd Dr PROCESS FOR PREPARING IRBESARTAN
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
SI21848A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en) 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
SI1812422T1 (sl) 2004-11-11 2014-05-30 Lek Pharmaceuticals D.D. Kristalna oblika irbesartana
PL1806130T3 (pl) * 2006-01-09 2010-08-31 Krka D D Novo Mesto Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
EP2134326B1 (en) * 2007-04-17 2011-11-16 Ratiopharm GmbH Pharmaceutical compositions comprising irbesartan
EA020209B1 (ru) * 2007-09-10 2014-09-30 Янссен Фармацевтика Н.В. Способ получения соединений, применимых в качестве ингибиторов натрийзависимого переносчика глюкозы
DE602007007968D1 (de) * 2007-11-28 2010-09-02 Lesvi Laboratorios Sl Pharmazeutische Formulierungen mit Irbesartan
WO2009072137A2 (en) * 2007-12-07 2009-06-11 Hetero Drugs Limited Process for pure irbesartan
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CZ302407B6 (cs) * 2009-03-12 2011-05-04 Univerzita Pardubice Zpusob prípravy 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-onu
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PT2451797E (pt) 2009-07-10 2013-06-25 Janssen Pharmaceutica Nv Processo de cristalização para o 1-(β-d-glucopiranosilo)-4-metilo-3-[5-(4-fluorofenilo)-2-tienilometilo]benzeno
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
SG10201500258WA (en) * 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
KR101913587B1 (ko) 2011-04-13 2018-10-31 얀센 파마슈티카 엔.브이. Sglt2의 억제제로서 유용한 화합물의 제조 방법
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN108368096B (zh) * 2015-12-21 2021-12-10 詹森药业有限公司 用于获得坎格列净半水合物晶体的结晶程序

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
EP1089994B9 (fr) 2008-08-27
EP1089994B1 (fr) 2004-09-08
JP2002518495A (ja) 2002-06-25
BR9912198A (pt) 2001-04-10
AU747887B2 (en) 2002-05-30
WO1999067236A1 (fr) 1999-12-29
US7008959B2 (en) 2006-03-07
UA55540C2 (ru) 2003-04-15
CN1127499C (zh) 2003-11-12
EA200001221A1 (ru) 2001-08-27
NO317786B1 (no) 2004-12-13
FR2780403A1 (fr) 1999-12-31
DE69920017D1 (de) 2004-10-14
ID27377A (id) 2001-04-05
HUP0103913A3 (en) 2003-01-28
CZ20004771A3 (en) 2001-06-13
CZ292868B6 (cs) 2003-12-17
IL140419A0 (en) 2002-02-10
ATE275562T1 (de) 2004-09-15
DE69920017T2 (de) 2005-09-22
ZA200007588B (en) 2001-06-11
NO20006645L (no) 2001-02-26
TR200003842T2 (tr) 2001-06-21
KR20010034917A (ko) 2001-04-25
NZ508842A (en) 2002-09-27
AU4048499A (en) 2000-01-10
NO20006645D0 (no) 2000-12-22
EA003410B1 (ru) 2003-04-24
PL345215A1 (en) 2001-12-03
SK20032000A3 (sk) 2001-05-10
US6800761B1 (en) 2004-10-05
EP1089994A1 (fr) 2001-04-11
HUP0103913A2 (hu) 2002-03-28
CN1306529A (zh) 2001-08-01
CA2335545A1 (en) 1999-12-29
US20050032862A1 (en) 2005-02-10
FR2780403B3 (fr) 2000-07-21

Similar Documents

Publication Publication Date Title
BG105069A (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
DE69525248D1 (de) Flächen-kristallines Wolframkarbid enthaltendes Hartmetall, Zusammensetzung zur Herstellung von flächen-kristallines Wolframkarbid und Verfahren zur Herstellung des Hartmetalls
NZ293695A (en) A transdermal implant containing fully destructurized starch
IL107590A0 (en) Biodegradable compositions comprising starch
AU3115989A (en) Method of making tobacco rod with enhanced firmness and product of this method
EP0916635A3 (en) Ceramic coatings containing layered porosity
PT98889A (pt) Processo para a preparacao de material para proteses osseas a base de produtos ceramicos osseos
IT1299982B1 (it) Metodo per la realizzazione di pacchetti di sigarette ed impianto per l'attuazione di tale metodo.
EP1016700A4 (en) WATER AND OIL REPELLENT COMPOSITION DISPERSED IN WATER AND METHOD FOR THE PRODUCTION THEREOF
DK1009385T3 (da) Kolesterolsænkende komposition
PL344042A1 (en) Compounds with growth hormone releasing properties
WO2003027232A3 (en) Method for producing biologically active products
BG102623A (en) New derivatives of benzoylguanadine, methods for their preparation and application for the manufacture of medicamentous forms
ATE33553T1 (de) Inerte pharmazeutische matrize aus polykaprolakton und verfahren zur herstellung einer oral galenischen form.
HUP0102009A3 (en) Synthetic polysaccharides, their method of production and pharmaceutical compositions containing the same
EP1172379A4 (en) FINE POWDER FROM MODIFIED POLYTETRAFLUORETHYLENE AND METHOD FOR THE PRODUCTION THEREOF
GB2246355B (en) Biodegradable composition,shaped article obtained therefrom and method of producing biodegradable compositions
HUP9601321A3 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them their use as pharmaceutical compositions or diagnostica, and the use of the said compds.
CA2336375A1 (en) Salt-stable modified starch
BG104291A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
EG22746A (en) Process and intermediates for the manufacture of pyridine 2,3 dicarboxylate compounds
PL337106A1 (en) Novel tetrahydronaphtalenes, method of obtaining them ,their application and aromatising composition containing them
PL331627A1 (en) Calcium formate containing material in the form of fine lumps and method of obtaining same
ES528792A0 (es) Procedimiento para la produccion de 3,4-di-(metilamino)-6-tercibutil-4,5-dihidro-1,2,4-triacin-5-ona
MY118015A (en) Method of crystallizing a tetrahydropyridine derivative and crystalline forms thereby obtained